PRNewswire - Monday January 8, 2001
The industry-oriented conference follows on the success of the 2000 meeting and is divided into four sections: Anti-HIV, HBV/HCV, influenza, and new technologies underpinning antiviral research.
Papers are to be presented on new work on HCV polymerase and protease inhibitors, pegylated interferon in combination therapies, chronic HCV therapies, and clinical trials and therapies for HBV. The keynote speaker for the hepatitis section is Jennifer Heathcote, M.D., Professor of Medicine, University of Toronto. Dr. Heathcote's keynote is entitled ``Clinical Issues in the Treatment of Chronic Hepatitis C.''
Other papers in this section will be presented by Merck, Schering Plough, Bristol-Myers Squibb, GlaxoSmithKline, Roche, and Vertex Pharmaceuticals. The Anti-HIV section is keynoted by John Coffin, Ph.D., of Tufts University and the National Cancer Institute; Dr. Coffin's talk is entitled ``Evolution & Current Status of HIV Drug Resistance.'' Data in related areas include CCR5 antagonists, HIV protease and NNRT inhibitors, and anti-HIV fusion inhibitors. Presenters include DuPont, Vertex, Trimeris, and Agouron Pharmaceuticals, and Merck Research Labs.
The influenza section is keynoted by Frederick Hayden, M.D., Professor of Internal Medicine & Pathology, University of Virginia School of Medicine, Charlottesville. Dr. Hayden's keynote is entitled ``Influenza Management: Advances & Unmet Needs.'' He shall be joined in the section by clinical updates on Zanamivir and Tamiflu, of GlaxoSmithKline and Roche Global Development, respectively, and a paper on R.W. Johnson PRI's neuraminidase inhibitor, RWJ-270201.
To request the agenda and/or register, please contact Sumeet Hora at shora@srinstitute.com (include affiliation and mailing address), or 212-967-0095, extension 261, or Camille Coward at ccoward@srinstitute.com . Contact Mark Alexay for information about exhibiting or conference sponsorship at malexay@srinstitute.com or 212-967-0095, extension 251.
SOURCE: Strategic Research Institute
010108
PR010102
Copyright © 2001 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.PRNewswire.com.
ÆGiS is made possible through unrestricted grants from Roxane Laboratories, Inc., iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content.